Vernalis PLC Vernalis Results of Annual General Meeting (7260Q)

TIDMVER

RNS Number : 7260Q

Vernalis PLC

01 December 2016

1 December 2016

LSE: VER

Vernalis Results of Annual General Meeting

Resolutions

Vernalis plc (LSE: VER) announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed.

All resolutions were approved on a show of hands. The number of proxy votes received for each resolution is set out below.

 
                                      For (including 
                                       discretionary 
 Resolution                               votes)*               Against*        Withheld 
--------------------------------  ----------------------  -------------------  ---------- 
 Ordinary Resolutions (requires 50% majority) 
----------------------------------------------------------------------------------------- 
 1. That the audited 
  accounts and related 
  reports of the directors 
  and auditors for the 
  12 month period ended                          (>99.99               (<0.01 
  30 June 2016 be received         481,517,407      %)       1,302       %)        178 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 2. That the remuneration 
  report contained within 
  the report and accounts 
  for the 12 month period 
  ended 30 June 2016                             (>98.62               (<1.38 
  be approved                      474,876,956      %)     6,639,291     %)       2,640 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 3. That Dr Fellner 
  be re-elected as a                             (>99.99               (<0.01 
  director                         479,611,759      %)      26,936       %)     1,880,192 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 4. That Ms Ferguson 
  be re-elected as a                             (<99.61               (>0.39 
  director                         479,635,151      %)     1,883,550     %)        186 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 5. That Mr Mackney 
  be re-elected as a                             (>99.99               (<0.01 
  director                         481,514,918      %)       3,708       %)        261 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 6. That PricewaterhouseCoopers 
  LLP be reappointed 
  auditors and the directors 
  be authorised to determine                     (>98.62               (<1.38 
  their remuneration               474,881,144      %)     6,637,552     %)        191 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 7. That the directors 
  be authorised to allot                         (>99.99               (<0.01 
  shares                           479,617,975      %)      19,306       %)     1,881,606 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 Special Resolutions (requires 75% majority) 
----------------------------------------------------------------------------------------- 
 8. That the directors 
  be authorised to disapply                      (>99.99               (<0.01 
  pre-emption rights               481,478,371      %)      36,956       %)       3,560 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 9. That the directors 
  be authorised to disapply 
  pre-emption rights 
  in connection with 
  an acquisition or specified                    (>99.60               (<0.40 
  capital investment               479,598,409      %)     1,916,786     %)       3,692 
--------------------------------  ------------  --------  ----------  -------  ---------- 
 

*NB: A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes

On 1 December 2016, there were 526,352,521 Vernalis plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

The full text of each resolution passed at the Annual General Meeting held earlier today, Thursday 1 December 2016, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.vernalis.com.

-- ends -

Enquiries:

 
 Vernalis:                                  [phone] 
 Ian Garland, Chief Executive Officer 
  David Mackney, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated 
  Adviser and Joint Broker):                [phone] 
 Dr Julian Feneley 
  Henry Fitzgerald-O'Connor 
  Rupert Winkler 
  Emma Gabriel 
 Shore Capital (Joint Broker):               [phone] 
 Bidhi Bhoma 
  Toby Gibbs 
 FTI Consulting:                            [phone] 
 Ben Atwell 
  Simon Conway 
  Stephanie Cuthbert 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR targeting the US prescription cough-cold market; Moxatag(R), a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.

For further information about Vernalis, please visit www.vernalis.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGLLFEFFALLIIR

(END) Dow Jones Newswires

December 01, 2016 08:00 ET (13:00 GMT)